Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.

Kroeze LI, Aslanyan MG, van Rooij A, Koorenhof-Scheele TN, Massop M, Carell T, Boezeman JB, Marie JP, Halkes CJ, de Witte T, Huls G, Suciu S, Wevers RA, van der Reijden BA, Jansen JH; EORTC Leukemia Group and GIMEMA.

Blood. 2014 Aug 14;124(7):1110-8. doi: 10.1182/blood-2013-08-518514. Epub 2014 Jul 1.

2.

The tetraspanin CD37 orchestrates the α(4)β(1) integrin-Akt signaling axis and supports long-lived plasma cell survival.

van Spriel AB, de Keijzer S, van der Schaaf A, Gartlan KH, Sofi M, Light A, Linssen PC, Boezeman JB, Zuidscherwoude M, Reinieren-Beeren I, Cambi A, Mackay F, Tarlinton DM, Figdor CG, Wright MD.

Sci Signal. 2012 Nov 13;5(250):ra82. doi: 10.1126/scisignal.2003113.

PMID:
23150881
3.

Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice.

van Lümig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM.

J Am Acad Dermatol. 2013 Jan;68(1):57-63. doi: 10.1016/j.jaad.2012.05.040. Epub 2012 Jul 28.

PMID:
22846689
4.

High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.

Luesink M, Hollink IH, van der Velden VH, Knops RH, Boezeman JB, de Haas V, Trka J, Baruchel A, Reinhardt D, van der Reijden BA, van den Heuvel-Eibrink MM, Zwaan CM, Jansen JH.

Blood. 2012 Sep 6;120(10):2064-75. doi: 10.1182/blood-2011-12-397083. Epub 2012 Jul 11.

5.

Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.

van Lümig PP, van de Kerkhof PC, Boezeman JB, Driessen RJ, de Jong EM.

J Eur Acad Dermatol Venereol. 2013 May;27(5):593-600. doi: 10.1111/j.1468-3083.2012.04496.x. Epub 2012 Mar 15.

PMID:
22416818
6.

A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinolysis.

van Geffen M, Loof A, Lap P, Boezeman J, Laros-van Gorkom BA, Brons P, Verbruggen B, van Kraaij M, van Heerde WL.

Hematology. 2011 Nov;16(6):327-36. doi: 10.1179/102453311X13085644680348.

PMID:
22183066
7.

Long-term efficacy of etanercept for psoriasis in daily practice.

Van Lümig PP, Driessen RJ, Boezeman JB, Van De Kerkhof PC, De Jong EM.

Br J Dermatol. 2012 Feb;166(2):445-7. doi: 10.1111/j.1365-2133.2011.10584.x. Epub 2011 Nov 17. No abstract available.

PMID:
21910699
8.

Safety of treatment with biologics for psoriasis in daily practice: 5-year data.

van Lümig PP, Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM.

J Eur Acad Dermatol Venereol. 2012 Mar;26(3):283-91. doi: 10.1111/j.1468-3083.2011.04044.x. Epub 2011 Mar 24.

PMID:
21435026
9.

Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab.

van Lümig PP, Driessen RJ, Roelofs-Thijssen MA, Boezeman JB, van de Kerkhof PC, de Jong EM.

Br J Dermatol. 2011 Aug;165(2):375-82. doi: 10.1111/j.1365-2133.2011.10329.x.

PMID:
21428975
10.

The lymphoid chemokine CCL21 triggers LFA-1 adhesive properties on human dendritic cells.

Eich C, de Vries IJ, Linssen PC, de Boer A, Boezeman JB, Figdor CG, Cambi A.

Immunol Cell Biol. 2011 Mar;89(3):458-65. doi: 10.1038/icb.2010.103. Epub 2010 Aug 31.

PMID:
20805842
11.

Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.

Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.

Br J Dermatol. 2010 Oct;163(4):838-46. doi: 10.1111/j.1365-2133.2010.09950.x. Epub 2010 Sep 2.

PMID:
20649798
12.

Treatment nonadherence and long-term effects of narrowband UV-B therapy in patients with psoriasis.

Evers AW, Kleinpenning MM, Smits T, Boezeman J, van de Kerkhof PC, Kraaimaat FW, Gerritsen MJ.

Arch Dermatol. 2010 Feb;146(2):198-9. doi: 10.1001/archdermatol.2009.382. No abstract available.

PMID:
20157036
13.

Itch and scratching as predictors of time to clearance of psoriasis with narrow-band ultraviolet B therapy.

Evers AW, Kleinpenning MM, Smits T, Boezeman J, van de Kerkhof PC, Kraaimaat FW, Gerritsen MJ.

Br J Dermatol. 2009 Sep;161(3):542-6. doi: 10.1111/j.1365-2133.2009.09236.x. Epub 2009 Apr 20.

PMID:
19538185
14.

Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens.

Kleinpenning MM, Smits T, Boezeman J, van de Kerkhof PC, Evers AW, Gerritsen MJ.

Br J Dermatol. 2009 Dec;161(6):1351-6. doi: 10.1111/j.1365-2133.2009.09212.x. Epub 2009 Apr 10.

PMID:
19466961
15.

Sorting catalytically active polymersome nanoreactors by flow cytometry.

Nallani M, Woestenenk R, de Hoog HP, van Dongen SF, Boezeman J, Cornelissen JJ, Nolte RJ, van Hest JC.

Small. 2009 May;5(10):1138-43. doi: 10.1002/smll.200801204. No abstract available.

PMID:
19235803
16.

Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study.

Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM.

Br J Dermatol. 2009 May;160(5):1075-82. doi: 10.1111/j.1365-2133.2008.09017.x. Epub 2009 Feb 4.

PMID:
19210503
17.

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM.

Br J Dermatol. 2009 Mar;160(3):670-5. doi: 10.1111/j.1365-2133.2008.09019.x. Epub 2008 Jan 28.

PMID:
19210502
18.

Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.

van der Velden HM, van Rossum MM, Blokx WA, Boezeman JB, Gerritsen MJ.

Dermatol Res Pract. 2009;2009:479183. doi: 10.1155/2009/479183. Epub 2009 Dec 31.

19.

Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases.

Hermans DJ, Boezeman JB, Van de Kerkhof PC, Rieu PN, Van der Vleuten CJ.

Eur J Dermatol. 2009 Mar-Apr;19(2):152-6. doi: 10.1684/ejd.2008.0576. Epub 2008 Dec 23.

PMID:
19106042
20.

Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies.

Driessen RJ, Boezeman JB, Van De Kerkhof PC, De Jong EM.

J Dermatolog Treat. 2009;20(1):42-7. doi: 10.1080/09546630802225702.

PMID:
18649164
21.

Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.

van Lingen RG, Körver JE, van de Kerkhof PC, Berends MA, van Rens DW, Langewouters AM, Boezeman JB, Seyger MM, de Jong EM.

Br J Dermatol. 2008 Jul;159(1):91-6. doi: 10.1111/j.1365-2133.2008.08618.x. Epub 2008 Jul 1.

PMID:
18476954
22.

Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome.

Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM.

Br J Dermatol. 2008 May;158(5):1098-106. doi: 10.1111/j.1365-2133.2008.08514.x. Epub 2008 Mar 29.

PMID:
18384440
23.

Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients.

van Lingen RG, van de Kerkhof PC, de Jong EM, Seyger MM, Boezeman JB, van Erp PE.

Exp Dermatol. 2008 Apr;17(4):343-8. doi: 10.1111/j.1600-0625.2007.00650.x.

PMID:
18315616
24.

Bone marrow mononuclear cells of MDS patients are characterized by in vitro proliferation and increased apoptosis independently of stromal interactions.

Span LF, Rutten E, Gemmink A, Boezeman JB, Raymakers RA, de Witte T.

Leuk Res. 2007 Dec;31(12):1659-67. Epub 2007 Jul 30.

PMID:
17659774
25.

Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.

Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM.

J Dermatolog Treat. 2007;18(2):76-83.

PMID:
17520463
26.

Heparan sulfate on activated glomerular endothelial cells and exogenous heparinoids influence the rolling and adhesion of leucocytes.

Rops AL, Jacobs CW, Linssen PC, Boezeman JB, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH, van der Vlag J, Berden JH.

Nephrol Dial Transplant. 2007 Apr;22(4):1070-7. Epub 2007 Jan 25.

PMID:
17255131
27.

A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation.

Körver JE, Vissers WH, van Rens DW, Pasch MC, van Erp PE, Boezeman JB, van De Kerkhof PC.

Br J Dermatol. 2007 Jan;156(1):130-7.

PMID:
17199579
28.

Isolation of FRET-positive cells using single 408-nm laser flow cytometry.

van Wageningen S, Pennings AH, van der Reijden BA, Boezeman JB, de Lange F, Jansen JH.

Cytometry A. 2006 Apr;69(4):291-8.

29.

Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38- cells.

de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ, Jansen JH, Raymakers RA.

Leukemia. 2006 Apr;20(4):750-4. No abstract available.

PMID:
16467867
30.

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy.

de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG.

Nat Biotechnol. 2005 Nov;23(11):1407-13. Epub 2005 Oct 30.

PMID:
16258544
31.

Programmed cell death is an intrinsic feature of MDS progenitors, predominantly found in the cluster-forming cells.

Span LF, Vierwinden G, Pennings AH, Boezeman JB, Raymakers RA, de Witte T.

Exp Hematol. 2005 Apr;33(4):435-42.

PMID:
15781334
32.

Functional characterization of beta1-integrin-positive epidermal cell populations.

van Rossum MM, Franssen ME, Cloin WA, van de Bosch GJ, Boezeman JB, Schalkwijk J, van de Kerkhof PC, van Erp PE.

Acta Derm Venereol. 2004;84(4):265-70.

PMID:
15339069
33.

Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.

Smit JV, de Jong EM, van Hooijdonk CA, Otero ME, Boezeman JB, van de Kerkhof PC.

J Am Acad Dermatol. 2004 Aug;51(2):257-64.

PMID:
15280845
34.

Monitoring hyperproliferative disorders in human skin: flow cytometry of changing cytokeratin expression.

Franssen ME, Boezeman JB, Van De Kerkhof PC, Van Erp PE.

Cytometry B Clin Cytom. 2004 Jan;57(1):32-9.

35.

An automated multi well cell track system to study leukocyte migration.

Krooshoop DJ, Torensma R, van den Bosch GJ, Nelissen JM, Figdor CG, Raymakers RA, Boezeman JB.

J Immunol Methods. 2003 Sep;280(1-2):89-102.

PMID:
12972190
36.

Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome.

Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M, Kucharekova M, Boezeman JB, Schalkwijk J.

Am J Hum Genet. 2003 Jul;73(1):214-7. No abstract available.

37.

Single-cell image analysis to assess ABC-transporter-mediated efflux in highly purified hematopoietic progenitors.

Raaijmakers HG, Van Den Bosch G, Boezeman J, De Witte T, Raymakers RA.

Cytometry. 2002 Dec 1;49(4):135-42.

38.

Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.

Schaap N, Schattenberg A, Mensink E, Preijers F, Hillegers M, Knops R, Pennings A, Boezeman J, Geurts van Kessel A, de Pauw B, de Witte T.

Leukemia. 2002 Jan;16(1):13-21.

39.

The dynamic process of apoptosis analyzed by flow cytometry using Annexin-V/propidium iodide and a modified in situ end labeling technique.

Span LF, Pennings AH, Vierwinden G, Boezeman JB, Raymakers RA, de Witte T.

Cytometry. 2002 Jan 1;47(1):24-31.

PMID:
11774346
40.

Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.

Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Boezeman J, Minderman H, de Witte TM.

Leukemia. 1999 Sep;13(9):1390-8.

PMID:
10482990
41.

Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis.

Gerritsen MJ, Boezeman JB, Elbers ME, van de Kerkhof PC.

Skin Pharmacol Appl Skin Physiol. 1998 May-Jun;11(3):133-9.

PMID:
9745140
42.

Multiparameter flow cytometry as a tool to evaluate antipsoriatic therapy.

Glade CP, van Erp PE, Boezeman JB, van de Kerkhof PC.

Br J Dermatol. 1997 Sep;137(3):367-75.

PMID:
9349331
43.

Automatic analysis of growth onset, growth rate and colony size of individual bone marrow progenitors.

Boezeman J, Raymakers R, Vierwinden G, Linssen P.

Cytometry. 1997 Aug 1;28(4):305-10.

PMID:
9266750
44.

A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity.

Smeets M, Raymakers R, Vierwinden G, Pennings A, van de Locht L, Wessels H, Boezeman J, de Witte T.

Br J Haematol. 1997 Feb;96(2):346-55.

PMID:
9029024
45.

Cell kinetic characterization of cultured human keratinocytes from normal and psoriatic individuals.

van Ruissen F, de Jongh GJ, van Erp PE, Boezeman JB, Schalkwijk J.

J Cell Physiol. 1996 Sep;168(3):684-94.

PMID:
8816923
47.

Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients.

de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC.

Dermatology. 1996;193(4):300-3.

PMID:
8993953
48.

Bias in nucleotide composition of antisense oligonucleotides.

Smetsers TF, Boezeman JB, Mensink EJ.

Antisense Nucleic Acid Drug Dev. 1996 Spring;6(1):63-7.

PMID:
8783797
49.

Detection of incorporated iododeoxyuridine in colonies by immunoperoxidase staining: a novel method to measure the proportion of cycling colony-forming cells.

Van der Lely N, Minderman H, Wessels H, Hillegers M, Linssen P, Pennings A, Brons P, Boezeman J, De Witte T.

Exp Hematol. 1995 Mar;23(3):236-43.

PMID:
7875241
50.

The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.

Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E.

Thromb Haemost. 1995 Feb;73(2):247-51.

PMID:
7792738

Supplemental Content

Loading ...
Support Center